Develops and manufactures the Versius modular surgical robotic system for minimally invasive surgery.
CMR Surgical Ltd.
Cambridge (GB) · Ely (GB)New on Amplifa
About CMR Surgical
CMR Surgical is a British medical technology company headquartered in Cambridge, which emerged from Cambridge Medical Robotics. The company develops and manufactures the Versius surgical robotic system and its further development, Versius Plus, a cart-based system with independent, modular arms designed for flexible use in various operating theatres without the need for a dedicated OR suite. The portfolio includes a complete instrument set, the 3D vision system, the integrated vLimeLite fluorescence visualisation for ICG imaging, and the digital ecosystem apps Versius Connect and Versius Team. Global manufacturing with a capacity of up to 500 systems per year is located in Ely (Cambridgeshire). Versius is used in Europe, Latin America, AMEA, Australia, India, Pakistan and the USA; more than 45,000 patients have been treated to date.
- Site
- CB24 9NG Cambridge, United Kingdom
- Processes
- Training and clinical support for surgical teams, Digital ecosystem apps: Versius Connect (procedural logbook for surgeons) and Versius Team, vLimeLite fluorescence visualisation (ICG imaging)
- Materials
- Versius Surgical Robotic System, Versius Plus, vLimeLite Fluorescence Visualisation, Versius Connect & Versius Team
- Founded
- 2014
- Employees
- 201-500
- Industries
- Medical technology, Surgical robotics, Minimally invasive surgery, Hospitals / Healthcare
- 01
Engineering & Design (Cambridge)
- 02
Manufacturing & Assembly (Ely)
- 03
Regulatory Approval (CE, FDA 510(k))
- 04
Training & Clinical Support
- 05
Digital Ecosystem (Versius Connect, Versius Team)
System Components & Technology
Versius Surgical Robotic System
Cart-based, modular robotic surgical system for minimally invasive procedures.
Versius Plus
Further development with integrated ICG fluorescence visualisation and digital ecosystem, FDA 510(k)-cleared for cholecystectomy.
vLimeLite Fluorescence Visualisation
Integrated ICG imaging for real-time assessment of vessels, perfusion and biliary anatomy.
Versius Connect & Versius Team
Digital apps with a procedural logbook for surgeons and a live dashboard on usage and system efficiency.
Sites
Cambridge
GBHeadquarters (Evolution Business Park, Milton Road)
Ely
GBGlobal Manufacturing Centre (Lancaster Way Business Park)
System Components
Inside the production
Industries
3 Anlagen & Maschinen
| Machine | Manufacturer / model | Quantity | Working area | Year built | Site |
|---|---|---|---|---|---|
| Surgical robotic system (cart-based, modular) | CMR Surgical Versius Plus | – | – | – | Cambridge/Ely, UK (global manufacturing site Ely) |
| Surgical robotic system | CMR Surgical Versius Surgical System | – | – | – | – |
| Fluorescence visualisation system (ICG imaging) | CMR Surgical vLimeLite | – | – | – | – |
Additional services
Reference customers
Company History
- 2014
Founded as Cambridge Medical Robotics.
- 2018
Renamed CMR Surgical (March).
- 2019
Achieved unicorn status.
- 2021
Series D financing round of over $600M at a $3 billion valuation; investors include Escala Capital, SoftBank Vision Fund 2, GE Healthcare and ABB Technology Ventures. Macquarie University Hospital (Australia) introduces Versius.
- 2022
Versius introduction for urological procedures in Pakistan; indication for thoracic use; successful transthoracic oesophagectomy study in Nature (October).
- 2023
King's Award for Enterprise (Innovation) for Versius; around 350 job cuts; $165M financing round (September); opening of a new UK manufacturing site with capacity of up to 500 systems/year (£10M investment); 20 NHS hospital partnerships (October).
- 2024
New ICG fluorescence imaging technology introduced (February); more than 20,000 Versius cases worldwide (March); FDA marketing authorisation for the next Versius system (October); first paediatric Versius procedure as part of an NHS study.
- 2025
Massimiliano Colella appointed CEO (January); over $200M in additional capital secured (April); FDA 510(k) clearance for Versius Plus (December).
- 2026
45,000 patients worldwide treated with Versius, second most used robotic surgical platform; US debut (March); 510(k) submission to the FDA for gynaecological indications (April); cooperation with NVIDIA for intelligent surgery (July); strategic alliance with Stryker (October).